Name | Number of supported studies  | Average coverage | |
|---|---|---|---|
| renal alpha-intercalated cell | 6 studies | 55% ± 18% | |
| goblet cell | 6 studies | 37% ± 3% | |
| kidney connecting tubule epithelial cell | 5 studies | 89% ± 10% | |
| kidney distal convoluted tubule epithelial cell | 5 studies | 60% ± 24% | |
| kidney loop of Henle epithelial cell | 5 studies | 23% ± 7% | |
| renal principal cell | 5 studies | 77% ± 12% | |
| enterocyte | 5 studies | 24% ± 9% | |
| epithelial cell | 5 studies | 34% ± 11% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| kidney | 100% | 24476.98 | 89 / 89 | 70% | 155.57 | 634 / 901 |
| ovary | 74% | 796.23 | 133 / 180 | 90% | 29.20 | 385 / 430 |
| intestine | 62% | 12117.17 | 602 / 966 | 96% | 120.27 | 504 / 527 |
| prostate | 83% | 1188.70 | 203 / 245 | 70% | 16.78 | 350 / 502 |
| stomach | 50% | 369.46 | 181 / 359 | 95% | 93.72 | 273 / 286 |
| uterus | 78% | 1334.34 | 133 / 170 | 66% | 21.30 | 305 / 459 |
| pancreas | 55% | 266.45 | 181 / 328 | 83% | 51.40 | 148 / 178 |
| breast | 60% | 1421.94 | 275 / 459 | 67% | 16.93 | 744 / 1118 |
| thymus | 94% | 1080.96 | 612 / 653 | 32% | 7.98 | 195 / 605 |
| esophagus | 39% | 340.60 | 560 / 1445 | 84% | 35.96 | 153 / 183 |
| ureter | 0% | 0 | 0 / 0 | 100% | 155.04 | 1 / 1 |
| bladder | 38% | 508.38 | 8 / 21 | 57% | 41.68 | 287 / 504 |
| lung | 37% | 212.08 | 211 / 578 | 52% | 13.21 | 605 / 1155 |
| adrenal gland | 56% | 402.69 | 144 / 258 | 27% | 7.31 | 63 / 230 |
| skin | 72% | 3769.66 | 1305 / 1809 | 3% | 0.77 | 15 / 472 |
| spleen | 75% | 597.28 | 181 / 241 | 0% | 0 | 0 / 0 |
| liver | 36% | 150.66 | 82 / 226 | 37% | 8.24 | 152 / 406 |
| tonsil | 0% | 0 | 0 / 0 | 40% | 6.89 | 18 / 45 |
| brain | 26% | 185.25 | 696 / 2642 | 3% | 0.51 | 23 / 705 |
| adipose | 17% | 132.62 | 201 / 1204 | 0% | 0 | 0 / 0 |
| heart | 4% | 15.74 | 31 / 861 | 0% | 0 | 0 / 0 |
| muscle | 1% | 5.59 | 8 / 803 | 0% | 0 | 0 / 0 |
| blood vessel | 0% | 2.76 | 2 / 1335 | 0% | 0 | 0 / 0 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| eye | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 80 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| lymph node | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 29 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| peripheral blood | 0% | 0 | 0 / 929 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| GO_0002017 | Biological process | regulation of blood volume by renal aldosterone |
| GO_0032868 | Biological process | response to insulin |
| GO_0009410 | Biological process | response to xenobiotic stimulus |
| GO_0051384 | Biological process | response to glucocorticoid |
| GO_0032094 | Biological process | response to food |
| GO_0001666 | Biological process | response to hypoxia |
| GO_0008211 | Biological process | glucocorticoid metabolic process |
| GO_0007565 | Biological process | female pregnancy |
| GO_0034650 | Biological process | cortisol metabolic process |
| GO_0043231 | Cellular component | intracellular membrane-bounded organelle |
| GO_0005789 | Cellular component | endoplasmic reticulum membrane |
| GO_0070523 | Molecular function | 11-beta-hydroxysteroid dehydrogenase (NAD+) activity |
| GO_0051287 | Molecular function | NAD binding |
| GO_0005496 | Molecular function | steroid binding |
| Gene name | HSD11B2 |
| Protein name | Hydroxysteroid 11-beta dehydrogenase 2 11-beta-hydroxysteroid dehydrogenase type 2 (11-DH2) (11-beta-HSD2) (EC 1.1.1.-) (11-beta-hydroxysteroid dehydrogenase type II) (11-HSD type II) (11-beta-HSD type II) (Corticosteroid 11-beta-dehydrogenase isozyme 2) (NAD-dependent 11-beta-hydroxysteroid dehydrogenase) (Short chain dehydrogenase/reductase family 9C member 3) |
| Synonyms | HSD11K SDR9C3 |
| Description | FUNCTION: Catalyzes the conversion of biologically active 11beta-hydroxyglucocorticoids (11beta-hydroxysteroid) such as cortisol, to inactive 11-ketoglucocorticoids (11-oxosteroid) such as cortisone, in the presence of NAD(+) . Functions as a dehydrogenase (oxidase), thereby decreasing the concentration of active glucocorticoids, thus protecting the nonselective mineralocorticoid receptor from occupation by glucocorticoids . Plays an important role in maintaining glucocorticoids balance during preimplantation and protects the fetus from excessive maternal corticosterone exposure (By similarity). Catalyzes the oxidation of 11beta-hydroxytestosterone (11beta,17beta-dihydroxyandrost-4-ene-3-one) to 11-ketotestosterone (17beta-hydroxyandrost-4-ene-3,11-dione), a major bioactive androgen . Catalyzes the conversion of 11beta-hydroxyandrostenedione (11beta-hydroxyandrost-4-ene-3,17-dione) to 11-ketoandrostenedione (androst-4-ene-3,11,17-trione), which can be further metabolized to 11-ketotestosterone . Converts 7-beta-25-dihydroxycholesterol to 7-oxo-25-hydroxycholesterol in vitro . 7-beta-25-dihydroxycholesterol (not 7-oxo-25-hydroxycholesterol) acts as a ligand for the G-protein-coupled receptor (GPCR) Epstein-Barr virus-induced gene 2 (EBI2) and may thereby regulate immune cell migration . May protect ovulating oocytes and fertilizing spermatozoa from the adverse effects of cortisol (By similarity). . |
| Accessions | P80365 R4GN04 ENST00000566606.1 ENST00000326152.6 |
